Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,012.82 USD
-1.77 (-0.17%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,012.82 USD
-1.77 (-0.17%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Zacks News
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.
Company News for Aug 4, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, REGN, HZNP, EXC
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
U.S. Stock Futures Rise on Strong Q2 Earnings
by Zacks Equity Research
Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.
Pre-markets Green on Strong Earnings Numbers
by Zacks Equity Research
Pre-markets Green on Strong Earnings Numbers.
Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.
What is in Store for Regeneron (REGN) This Earnings Season?
by Zacks Equity Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed the most recent trading day at $587.28, moving +0.2% from the previous trading session.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
by Zacks Equity Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $595.73 in the latest trading session, marking a +1.54% move from the prior day.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
by Zacks Equity Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds
by Kinjel Shah
Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.
The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals
by Zacks Equity Research
Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Regeneron (REGN) Stock Moves -0.71%: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $610.09, marking a -0.71% move from the previous day.
Top Stock Reports for Coca-Cola, Merck & Toyota Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Merck & Co., Inc. (MRK) and Toyota Motor Corp. (TM).
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $594.90 in the latest trading session, marking a -0.28% move from the prior day.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB